Quick Answer
Eton Pharmaceuticals, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $79.95 million for the year ending 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +104.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Eton Pharmaceuticals, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 8,236.8%.
- Historical annual values: Fiscal year 2025: $79.95 million | Fiscal year 2024: $39.01 million | Fiscal year 2023: $31.64 million | Fiscal year 2022: $21.25 million | Fiscal year 2021: $21.83 million | Fiscal year 2020: $39.0 thousand | Fiscal year 2019: $959.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: